A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group,
efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and
premenarchal female subjects 6 to 11 years of age with a diagnosis of PAR.